Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery

Żak, Magdalena; Zangi, Lior

doi:10.3390/pharmaceutics13101675

Cited by 50 publications

(26 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These large eVLPs have a size greater than 100 nm, so there is a chance that they might aggregate at the site of injection and will not reach the lymph nodes that limit their application ( Keikha et al, 2021 ). In comparison, lipid nanoparticles carrying mRNA vaccines have a size range of 100 nm or less and show high efficacy in delivering vaccines to the targeted site ( Editorial., 2021 ; Żak and Zangi, 2021 ).…”

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.

show abstract

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Depending on the LNP composition, most ionizable lipid-based formulations have been identified from screening for liver delivery and require coating by ApoE to transfect cells in vitro, and presumably, in vivo receptor-mediated endocytosis [ 59 , 60 ]. Although they lack true tissue tropism, preferential tissue targeting and certain biodistribution profiles can be achieved by either directly engineering targeting motifs, route of administration (ROA), or altering the composition and physicochemical characteristics of the particles [ 57 , 61 , 62 ].…”

Section: Delivery–host Cell Interactionsmentioning

confidence: 99%

Next generation self-replicating RNA vectors for vaccines and immunotherapies

Aliahmad¹,

Miyake-Stoner²,

Geall³

et al. 2022

Cancer Gene Ther

View full text Add to dashboard Cite

RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy. In addition to conventional mRNA platforms now approved for prophylactic SARS-CoV2 vaccines, synthetic self-replicating RNA vaccines are currently being evaluated in the clinic for infectious disease and oncology. The prototypical srRNA vectors in clinical development are derived from alphaviruses, specifically Venezuelan Equine Encephalitis Virus (VEEV). While non-VEEV alphaviral strains have been explored as single cycle viral particles, their use as synthetic vectors largely remains under-utilized in clinical applications. Here we describe the potential commonalities and differences in synthetic alphaviral srRNA vectors in host cell interactions, immunogenicity, cellular delivery, and cargo expression. Thus, unlike the current thinking that VEEV-based srRNA is a one-size-fits-all platform, we argue that a new drug development approach leveraging panels of customizable, synthetic srRNA vectors will be required for clinical success.

show abstract

“…Preclinical studies for Onpattro® most likely used MAR, as they contain data on intracellular radioactivity in hepatocytes, hepatic vascular cells (cell type not specified), and liver sinusoid lumen [22] . Obtaining cellular resolution has a more prominent role when cell-targeting moieties are used on LNPs, for example [71] , [72] , [73] , [74] , [75] , [76] . In this regard, MAR can sometimes (depending on reagent compatibility) be coupled to immunohistochemistry to verify targeted delivery [52] .…”

Section: Techniques Used For Authorized Rna Therapeuticsmentioning

confidence: 99%